CA3125625A1 - Inhibitors of cgas activity as therapeutic agents - Google Patents

Inhibitors of cgas activity as therapeutic agents Download PDF

Info

Publication number
CA3125625A1
CA3125625A1 CA3125625A CA3125625A CA3125625A1 CA 3125625 A1 CA3125625 A1 CA 3125625A1 CA 3125625 A CA3125625 A CA 3125625A CA 3125625 A CA3125625 A CA 3125625A CA 3125625 A1 CA3125625 A1 CA 3125625A1
Authority
CA
Canada
Prior art keywords
pyrimidin
methylbenzofuro
carboxylic acid
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3125625A
Other languages
English (en)
French (fr)
Inventor
Robert G. Lowery
Meera Kumar
Matthew Boxer
David Maloney
Susan BOYD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of CA3125625A1 publication Critical patent/CA3125625A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3125625A 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents Pending CA3125625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788624P 2019-01-04 2019-01-04
US62/788,624 2019-01-04
PCT/US2020/012243 WO2020142729A1 (en) 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents

Publications (1)

Publication Number Publication Date
CA3125625A1 true CA3125625A1 (en) 2020-07-09

Family

ID=72338800

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3125625A Pending CA3125625A1 (en) 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents

Country Status (8)

Country Link
US (1) US20220073532A1 (https=)
EP (1) EP3906241A4 (https=)
JP (1) JP7507161B2 (https=)
KR (1) KR20210112316A (https=)
CN (1) CN113302194A (https=)
AU (1) AU2020205114A1 (https=)
CA (1) CA3125625A1 (https=)
WO (1) WO2020142729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021349249A1 (en) * 2020-09-24 2023-04-13 Ventus Therapeutics U.S., Inc. Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals
US20240174684A1 (en) * 2021-02-11 2024-05-30 Bellbrook Labs, Llc INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
CN117337291A (zh) * 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有C-连接环状取代基的吡啶衍生物
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025172882A1 (en) 2024-02-14 2025-08-21 Janssen Pharmaceutica Nv Substituted pyrrolidine-2-carboxylic acid derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP1812113A1 (en) * 2004-11-11 2007-08-01 Argenta Discovery Limited Pyrimidine compounds as histamine modulators
EP1767537A1 (en) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
KR20250065420A (ko) * 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치
WO2019084271A1 (en) * 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
US20220073532A1 (en) 2022-03-10
EP3906241A1 (en) 2021-11-10
EP3906241A4 (en) 2022-11-02
AU2020205114A1 (en) 2021-07-22
WO2020142729A1 (en) 2020-07-09
KR20210112316A (ko) 2021-09-14
JP2022518148A (ja) 2022-03-14
JP7507161B2 (ja) 2024-06-27
CN113302194A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
CA3125625A1 (en) Inhibitors of cgas activity as therapeutic agents
US20230219926A1 (en) Substituted carboxamides as inhibitors of wdr5 protein-protein binding
ES2866152T3 (es) Derivados de tirosina amida como inhibidores de la Rho-quinasa
JP6759514B2 (ja) ブロモドメインに対して活性な化合物
JP7507162B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
EP3354640A2 (en) Mif inhibitors and their uses
TW202016094A (zh) 週期素依賴性激酶抑制劑
US20190119264A1 (en) Inhibitors of wdr5 protein-protein binding
US20180222904A1 (en) Bruton's tyrosine kinase inhibitors
US20210284635A1 (en) Novel naphthyridinone derivatives and their use in the treatment of arrhythmia
JP2010523530A (ja) タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン
CA3206520A1 (en) Inhibitors of cgas activity as therapeutic agents
TW202448435A (zh) 經取代之噻二唑基化合物
EP4263547B1 (en) Dihydrofuropyridine derivatives as rho- kinase inhibitors
US12325701B2 (en) YKL-40 inhibitors and their therapeutic
TW201441193A (zh) 吡啶酮化合物
JP2025528113A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
CN121895236A (zh) 一种itk激酶选择性抑制剂及其应用
EA048604B1 (ru) ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ С N-ПРИСОЕДИНЕННЫМИ ЦИКЛИЧЕСКИМИ ЗАМЕСТИТЕЛЯМИ В КАЧЕСТВЕ ИНГИБИТОРОВ cGAS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260216